Infectious Disease · 12 h ago
Phase 3 Trial Examines Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment
An NEJM listing identifies a phase 3 trial of weekly oral islatravir–lenacapavir for HIV-1 treatment. The supplied text contains only bibliographic information, with no sample size, methods, efficacy results, or safety findings.
- Phase 3 trial evaluates weekly oral HIV-1 treatment.
- Sample size and efficacy and safety findings are not provided.
AI summary · Not yet editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
NEJM – Current issue: Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.